{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:19:55Z","timestamp":1745554795032,"version":"3.40.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The advanced disease management (ADM) package, which aims to reduce morbidity and mortality in people with Advanced HIV disease (AHD, WHO stage III\/IV and\/or CD4 count\u2009&lt;\u2009200 cells\/mm<jats:sup>3<\/jats:sup> or age\u2009&lt;\u20095 years), is not fully implemented in India. We assessed the feasibility of implementing the full WHO ADM package as part of routine HIV care under the programmatic setting in antiretroviral therapy centers of Mumbai.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We implemented the ADM package (screening, treatment, and prophylaxis for major opportunistic infections, rapid ART initiation, and ART adherence support) in 17 ART centers from October 2020 to December 2021. Treatment na\u00efve and experienced persons with AHD, including children, were enrolled. We assessed the feasibility through coverage of ADM package components and reported the proportion of rapid ART initiation (\u2264\u20097 days), cotrimoxazole prophylaxis, TB preventive treatment (TPT) for those eligible [(excluded active TB disease (<jats:italic>n<\/jats:italic>\u2009=\u2009280) and those completed TPT prior to enrolment (<jats:italic>n<\/jats:italic>\u2009=\u20091,186)], TB-LAM screening (excluded current TB disease), and cryptococcal antigen (CrAg) assay (excluded children\u2009&lt;\u200910 years of age). We used a point of care test for TB (LAM) and cryptococcus (CrAg) screening. We followed the prospective cohort for one year (through 31 July 2022) to document outcomes for survival and lost to follow- up (LTFU).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified 4,334 PLHIV with AHD and provided the full ADM package to 64% (2,779\/4,334); 297 did not receive ADM (146 died, 151 LTFU), and 1,258 received routine standard of care (587 had TB, 366 were at decentralized sites, and 305 LAM\/CrAg kits were not available) with existing ART center staff. Nearly 78% (385\/494) of treatment na\u00efve were rapidly initiated on ART. Nearly 82% (1,129\/1,383) and 99% (2,751\/2,779) received TPT and cotrimoxazole prophylaxis, respectively. Of the eligible, 99% (2,508\/2,524) and 98% (2,715\/2,758) were screened for TB and cryptococcal infection, respectively. At the end of 12 months, 88% (2,458\/2,779) were alive, 8% (210\/2,779) died, and 4% (111\/2,779) were LTFU. Mean survival time was significantly (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) higher among treatment experienced people; 11.6 months (95% CI: 11.5,11.7) compared to treatment na\u00efve people 10.8 months (95% CI: 10.5,11.0).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>With careful anticipatory planning, stakeholder engagement, and training, implementing the full ADM package is feasible in a routine program setting with existing human resources. Additional intensive case management may be necessary for the reduction of mortality among treatment na\u00efve PLHIV.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12913-025-12572-5","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:20:22Z","timestamp":1745500822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating HIV advanced disease management into a routine program setting: cohort from Mumbai, India"],"prefix":"10.1186","volume":"25","author":[{"given":"Shrikala","family":"Acharya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh Reddy","family":"Allam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Kumar","family":"Karanjkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhirubhai","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol","family":"Palkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Todmal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Koli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Dhande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nalini","family":"Chava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay V","family":"Yeldandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Harshana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshu","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Nyendak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"12572_CR1","unstructured":"2023 UNAIDS Fact sheet. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf"},{"issue":"suppl2","key":"12572_CR2","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1093\/cid\/ciy045","volume":"66","author":"S Carmona","year":"2018","unstructured":"Carmona S, Bor J, Nattey C, Maughan-Brown B, Maskew M, Fox MP, Glencross DK, Ford N, MacLeod WB. Persistent high burden of advanced HIV disease among patients seeking care in South Africa\u2019s National HIV program: data from a nationwide laboratory cohort. Clin Infect Dis. 2018;66(suppl2):S111\u20137.","journal-title":"Clin Infect Dis"},{"issue":"suppl2","key":"12572_CR3","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1093\/cid\/cix1140","volume":"66","author":"M Osler","year":"2018","unstructured":"Osler M, Hilderbrand K, Goemaere E, Ford N, Smith M, Meintjes G, Kruger J, Govender NP, Boulle A. The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa. Clin Infect Dis. 2018;66(suppl2):S118\u201325.","journal-title":"Clin Infect Dis"},{"key":"12572_CR4","unstructured":"World Health Organization. Package of care for children and adolescents with advanced HIV disease: stop AIDS. Technical brief. Geneva: World Health Organization. 2020. Licence: CC BY-NC-SA 3.0 IGO. Accessed Jul 2023 https:\/\/www.who.int\/publications\/i\/item\/9789240008045"},{"key":"12572_CR5","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization. 2021. License: CC BY-NC-SA 3.0 IGO. Accessed Jun 2023 https:\/\/www.who.int\/publications\/i\/item\/9789240031593"},{"key":"12572_CR6","unstructured":"National AIDS, Control Organization. Fifth edition,. Sankalak: Status of National AIDS Response (2023). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India. 2023. Accessed Jan 2024 https:\/\/naco.gov.in\/sites\/default\/files\/Sankalak%20Booklet.pdf"},{"key":"12572_CR7","unstructured":"National AIDS Control Organization. National Guidelines for HIV Care and Treatment. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India. 2021. Accessed Feb 2022 https:\/\/naco.gov.in\/sites\/default\/files\/National_Guidelines_for_HIV_Care_and_Treatment_2021.pdf"},{"issue":"suppl2","key":"12572_CR8","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1093\/cid\/cix1139","volume":"66","author":"N Ford","year":"2018","unstructured":"Ford N, Meintjes G, Calmy A, Bygrave H, Migone C, Vitoria M, Penazzato M, Vojnov L, Doherty M. Guideline development group for managing advanced HIV disease and rapid initiation of antiretroviral therapy. managing advanced HIV disease in a public health approach. Clin Infect Dis. 2018;66(suppl2):S106\u2013SS110.","journal-title":"Clin Infect Dis"},{"issue":"suppl2","key":"12572_CR9","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1093\/cid\/cix1138","volume":"66","author":"A Calmy","year":"2018","unstructured":"Calmy A, Ford N, Meintjes G. The persistent challenge of advanced HIV disease and AIDS in the era of antiretroviral therapy. Clin Infect Dis. 2018;66(suppl2):S103\u2013SS105.","journal-title":"Clin Infect Dis"},{"key":"12572_CR10","volume-title":"Operational Guidelines for HIV Care and Treatment","author":"National AIDS Control Organization","year":"2021","unstructured":"National AIDS Control Organization. Operational guidelines for HIV care and treatment. Ministry of Health and Family Welfare, Government of India; 2021."},{"issue":"9","key":"12572_CR11","doi-asserted-by":"publisher","first-page":"e0273970","DOI":"10.1371\/journal.pone.0273970","volume":"17","author":"S Acharya","year":"2022","unstructured":"Acharya S, Deshpande P, Asirvatham ES, Palkar A, Sarman CJ, Laxmeshwar C, Setia MS, Rathod D, Koli S, Dale J, Yeldandi V, Allam R, Agarwal R, Verma S, Upadhyaya S, Nyendak M. Utility of the lateral flow urine Lipoarabinomannan tuberculosis assay in patients with advanced HIV disease at antiretroviral therapy centres in Mumbai, India. PLoS ONE. 2022;17(9):e0273970.","journal-title":"PLoS ONE"},{"issue":"6","key":"12572_CR12","doi-asserted-by":"publisher","first-page":"e070500","DOI":"10.1136\/bmjopen-2022-070500","volume":"13","author":"S Acharya","year":"2023","unstructured":"Acharya S, Allam RR, Karanjkar VK, Rathod D, Mahajan R, Deshpande P, Palkar A, Todmal S, Koli S, Dhande S, Dale J, Yeldandi VV, Harshana A, Agarwal R, Upadhyaya S, Nyendak M. Implementation of point-of-care testing and prevalence of Cryptococcal antigenaemia among patients with advanced HIV disease in Mumbai, India. BMJ Open. 2023;13(6):e070500.","journal-title":"BMJ Open"},{"key":"12572_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13012-015-0242-0","volume":"10","author":"P Nilsen","year":"2015","unstructured":"Nilsen P. Making sense of implementation theories, models, and frameworks. Implement Sci. 2015;10:53.","journal-title":"Implement Sci"},{"issue":"2","key":"12572_CR14","first-page":"89","volume":"36","author":"ID Graham","year":"2004","unstructured":"Graham ID, Logan J. Innovations in knowledge transfer and continuity of care. Can J Nurs Res. 2004;36(2):89\u2013103.","journal-title":"Can J Nurs Res"},{"issue":"2","key":"12572_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1075547098020002004","volume":"20","author":"J Logan","year":"1998","unstructured":"Logan J, Graham ID. Toward a comprehensive interdisciplinary model of health care research use. Sci Communication. 1998;20(2):227\u201346.","journal-title":"Sci Communication"},{"issue":"4","key":"12572_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.0887-378X.2004.00325.x","volume":"82","author":"T Greenhalgh","year":"2004","unstructured":"Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82(4):581\u2013629.","journal-title":"Milbank Q"},{"key":"12572_CR17","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach.\u00a02nd ed. Geneva: WHO; 2016. ISBN 9789241549684. Accessed Jun 2022 https:\/\/www.who.int\/publications\/i\/item\/9789241549684."},{"key":"12572_CR18","doi-asserted-by":"publisher","first-page":"e0183656","DOI":"10.1371\/journal.pone.0183656","volume":"12","author":"F Rick","year":"2017","unstructured":"Rick F, Niyibizi AA, Shroufi A, et al. Cryptococcal antigen screening by Lay cadres using a rapid test at the point of care: a feasibility study in rural Lesotho. PLoS ONE. 2017;12:e0183656.","journal-title":"PLoS ONE"},{"issue":"12","key":"12572_CR19","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/cid\/cis797","volume":"55","author":"AS Walker","year":"2012","unstructured":"Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A, Katabira E, Gilks CF, Kityo C, Nahirya-Ntege P, Nathoo K, Gibb DM. DART and ARROW trial teams. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis. 2012;55(12):1707\u201318.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"12572_CR20","doi-asserted-by":"publisher","first-page":"e0171675","DOI":"10.1371\/journal.pone.0171675","volume":"12","author":"N Cassim","year":"2017","unstructured":"Cassim N, Schnippel K, Coetzee LM, Glencross DK. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV\u2009+\u2009patients with CD4 counts less than 100 cells\/\u00b5l using a lateral flow assay (LFA) at a typical busy CD4 laboratory in South Africa. PLoS ONE. 2017;12(2):e0171675.","journal-title":"PLoS ONE"},{"key":"#cr-split#-12572_CR21.1","unstructured":"WHO. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV-Policy update. (2019). Geneva: World Health Organization"},{"key":"#cr-split#-12572_CR21.2","unstructured":"Licence: CC BY-NC-SA 3.0 IGO. 2019. Accessed Jun 2021 https:\/\/www.who.int\/publications\/i\/item\/9789241550604"},{"key":"12572_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.12688\/gatesopenres.13112.1","volume":"4","author":"DN Singhroy","year":"2020","unstructured":"Singhroy DN, MacLean E, Kohli M, Lessem E, Branigan D, England K, Suleiman K, Drain PK, Ruhwald M, Schumacher S, Denkinger CM, Waning B, Van Gemert W, Pai M. Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV\/AIDS burden: current landscape and barriers. Gates Open Res. 2020;4:24.","journal-title":"Gates Open Res"},{"issue":"7","key":"12572_CR23","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1016\/S2352-3018(20)30101-6","volume":"7","author":"Z Ndlovu","year":"2020","unstructured":"Ndlovu Z, Burton R, Stewart R, Bygrave H, Roberts T, Fajardo E, Mataka A, Szumilin E, Kerschberger B, Van Cutsem G, Ellman T. Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives. Lancet HIV. 2020;7(7):e514\u201320.","journal-title":"Lancet HIV"},{"issue":"7","key":"12572_CR24","doi-asserted-by":"publisher","first-page":"e0158986","DOI":"10.1371\/journal.pone.0158986","volume":"11","author":"BA Larson","year":"2016","unstructured":"Larson BA, Rockers PC, Bonawitz R, Sriruttan C, Glencross DK, Cassim N, Coetzee LM, Greene GS, Chiller TM, Vallabhaneni S, Long L, van Rensburg C, Govender NP. Screening HIV-Infected patients with low CD4 counts for Cryptococcal antigenemia prior to initiation of antiretroviral therapy: cost effectiveness of alternative screening strategies in South Africa. PLoS ONE. 2016;11(7):e0158986.","journal-title":"PLoS ONE"},{"key":"12572_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1748-5908-7-32","volume":"7","author":"GA Aarons","year":"2012","unstructured":"Aarons GA, Green AE, Palinkas LA, Self-Brown S, Whitaker DJ, Lutzker JR, Silovsky JF, Hecht DB, Chaffin MJ. Dynamic adaptation process to implement an evidence-based child maltreatment intervention. Implement Sci. 2012;7:32.","journal-title":"Implement Sci"},{"issue":"1","key":"12572_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QAD.0000000000001671","volume":"32","author":"N Ford","year":"2018","unstructured":"Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, Mills EJ, Meintjes G, Vitoria M, Doherty M, Shubber Z. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS. 2018;32(1):17\u201323.","journal-title":"AIDS"},{"key":"12572_CR27","unstructured":"National AIDS, Control Organization. Guidelines on Prevention and Management of TB in PLHIV at ART Centers. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India. 2016. Accessed Jun 2022 https:\/\/tbcindia.gov.in\/WriteReadData\/l892s\/8466816483Guidelines%20on%20Prevention%20and%20Management08Dec16_1.pdf"},{"issue":"4","key":"12572_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/jcm10040716","volume":"10","author":"J Portilla-Tamarit","year":"2021","unstructured":"Portilla-Tamarit J, Reus S, Portilla I, Fuster Ruiz-de-Apodaca MJ, Portilla J. Impact of advanced HIV disease on quality of life and mortality in the era of combined antiretroviral treatment. J Clin Med. 2021;10(4):716.","journal-title":"J Clin Med"},{"issue":"1","key":"12572_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0000000000001112","volume":"73","author":"AT Brennan","year":"2016","unstructured":"Brennan AT, Long L, Useem J, Garrison L, Fox MP. Mortality in the first 3 months on antiretroviral therapy among HIV-Positive adults in Low- and Middle-income countries: A Meta-analysis. J Acquir Immune Defic Syndr. 2016;73(1):1\u201310.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"12572_CR30","unstructured":"WHO. Providing care to people with advanced HIV disease who are seriously ill: policy brief. Geneva: World Health Organization. 2023. Licence: CC BY-NC-SA 3.0 IGO. Accessed Sep 2023 https:\/\/www.who.int\/publications\/i\/item\/9789240068650"},{"issue":"1","key":"12572_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12981-021-00353-z","volume":"18","author":"KL Workie","year":"2021","unstructured":"Workie KL, Birhan TY, Angaw DA. Predictors of mortality rate among adult HIV-positive patients on antiretroviral therapy in Metema hospital, Northwest Ethiopia: a retrospective follow-up study. AIDS Res Ther. 2021;18(1):27.","journal-title":"AIDS Res Ther"},{"issue":"3","key":"12572_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2989\/16085906.2022.2056062","volume":"21","author":"A Byamukama","year":"2022","unstructured":"Byamukama A, Golding PM. Predictors of mortality among people living with HIV in the test and treat era within rural Uganda: a retrospective cohort study. Afr J AIDS Res. 2022;21(3):231\u20138.","journal-title":"Afr J AIDS Res"},{"key":"12572_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1615822","volume":"377","author":"J Hakim","year":"2017","unstructured":"Hakim J, Musiime V, Szubert AJ, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377:233\u201345.","journal-title":"N Engl J Med"},{"issue":"9983","key":"12572_CR34","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(15)60164-7","volume":"385","author":"S Mfinanga","year":"2015","unstructured":"Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, Chijoka C, Masasi A, Kimaro G, Ngowi B, Kahwa A, Mwaba P, Harrison TS, Egwaga S, Jaffar S. REMSTART trial team. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385(9983):2173\u201382.","journal-title":"Lancet"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12572-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12572-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12572-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:20:30Z","timestamp":1745500830000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12572-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12572"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12572-5","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was received for secondary data analysis from the ethics committee of Mumbai Districts AIDS Control Society (MDACS) (Ref: MDACS\/140\/STI Dated 27\/10\/2021). The CDC reviewed this activity, deemed research not involving human subjects, and was conducted consistent with applicable federal law and CDC policy.There was a waiver of consent by the ethics committee of Mumbai Districts AIDS Control Society (MDACS)(Ref: MDACS\/140\/STI Dated 27\/10\/2021) as this is a routine program intervention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"595"}}